Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 17

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 17
---
 Offerings, we entered into a placement agency agreement, or the Placement Agent Agreement, with Ladenburg Thalmann
& Co. Inc., or Ladenburg, pursuant to which we engaged Ladenburg as the exclusive placement agent for the Offerings. We agreed to
pay Ladenburg a cash fee in an amount equal to 8.0% of the aggregate gross proceeds of the Offerings and to issue to Ladenburg or its
designees the July 2024 Placement Agent Warrants. We also agreed to pay Ladenburg a management fee equal to 1.0% of the gross proceeds
raised in the Offerings and an expense allowance of up to $85,000 for legal fees and other out-of-pocket expenses. The July 2024 Placement
Agent Warrant has substantially the same terms as the Series J Warrants, except that the exercise price of the July 2024 Placement Agent
Warrants is $31.25 and the term of the July 2024 Placement Agent Warrants will terminate on the three-year anniversary of the initial
exercise date.

Warrant Inducement

On
May 22, 2024, we entered into letter agreements, or the Warrant Agreements, with certain accredited investors, collectively referred to
as the Holders, that were holders of an aggregate of 62,906 of our outstanding Series E warrants exercisable for $55.00 per Depositary
Share, or Series E Warrants, and an aggregate of 61,275 of our outstanding Series F warrants exercisable for $55.00 per Depositary Share,
or Series F Warrants, issued on December 21, 2023. Pursuant to the Warrant Agreements, the Holders agreed to exercise the Series E Warrants
and Series F Warrants, as applicable, at a reduced exercise price of $37.50 per Depositary Share; provided that the Warrant Agreements
provide that in the event that any warrant exercise would otherwise cause a holder to exceed the beneficial ownership limitation set forth
in the applicable warrants, we would only issue such number of shares to such holder that would not cause such holder to exceed the maximum
number of shares permitted thereunder, with the balance to be held in abeyance for the benefit of such holder until notice from such holder
that the balance (or portion thereof) may be issued in compliance with such limitation, which abeyance is evidenced through the warrants
which shall be deemed prepaid thereafter (including the payment in full of the